Ependymoblastoma (ETMR)

Categories: Cancer diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ependymoblastoma

MalaCards integrated aliases for Ependymoblastoma:

Name: Ependymoblastoma 12 74 52 58 54 15 71
Embryonal Tumor with Abundant Neuropil and True Rosettes 52
Embryonal Tumor with Multilayered Rosettes 52
Neuroectodermal Tumors Primitive 52
Etantr 52
Etmr 52


Orphanet epidemiological data:

Inheritance: Not applicable; Age of onset: Infancy,Neonatal;


Orphanet: 58  
Rare neurological diseases

External Ids:

Disease Ontology 12 DOID:4794
MeSH 43 D018242
NCIt 49 C4915
SNOMED-CT 67 715901002
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0700367
Orphanet 58 ORPHA251880
UMLS 71 C0700367

Summaries for Ependymoblastoma

MalaCards based summary : Ependymoblastoma, also known as embryonal tumor with abundant neuropil and true rosettes, is related to ewing sarcoma and anaplastic ependymoma, and has symptoms including vomiting and headache. An important gene associated with Ependymoblastoma is NES (Nestin), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Donepezil and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and lung, and related phenotypes are muscle and nervous system

Wikipedia : 74 Primitive neuroectodermal tumor is a malignant (cancerous) neural crest tumor. It is a rare tumor,... more...

Related Diseases for Ependymoblastoma

Diseases in the Ependymoblastoma family:

Adult Ependymoblastoma

Diseases related to Ependymoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 31.9 VIM SYP MYCN ENO2
2 anaplastic ependymoma 30.7 VIM SYP GFAP
3 rhabdoid tumor predisposition syndrome 1 30.4 VIM SYP SMARCB1
4 benign ependymoma 30.1 VIM SYP NES GFAP ENO2
5 central nervous system cancer 30.0 SYP SMARCB1 NES MYCN GFAP
6 atypical teratoid rhabdoid tumor 29.8 VIM SYP SMARCB1 LIN28A GFAP
7 ganglioneuroblastoma 29.6 SYP MYCN ENO2
8 melanotic neuroectodermal tumor 29.6 VIM SYP GFAP ENO2
9 astroblastoma 29.0 VIM SYP NES GFAP FOXR2 ENO2
10 medulloepithelioma 29.0 VIM SYP SMARCB1 NES LIN28A GFAP
11 hydrocephalus 28.9 VIM SYP SMARCB1 NGF NES GFAP
12 neuroblastoma 28.8 SYP NGF NES MYCN MET GFAP
13 medulloblastoma 28.3 VIM SYP SMARCB1 NGF NES MYCN
14 pediatric infratentorial ependymoblastoma 12.2
15 adult ependymoblastoma 12.2
16 pediatric cerebral ependymoblastoma 12.2
17 pediatric supratentorial ependymoma 11.4
18 embryonal carcinoma 10.6
19 cellular ependymoma 10.6
20 anaplastic ganglioglioma 10.5 NES GFAP
21 chromosomal triplication 10.5
22 central nervous system immature teratoma 10.5 NES GFAP
23 odontoma 10.5 VIM NES
24 malignant ependymoma 10.4
25 cutaneous leiomyosarcoma 10.4 VIM GFAP
26 primary hepatic neuroendocrine carcinoma 10.4 VIM SYP
27 glomangiomyoma 10.4 VIM SYP
28 extraventricular neurocytoma 10.4 SYP GFAP
29 parachordoma 10.4 VIM GFAP
30 lung combined type small cell carcinoma 10.4 SYP GFAP
31 esophageal adenoid cystic carcinoma 10.4 VIM SYP
32 tanycytic ependymoma 10.4 SYP GFAP
33 chiari malformation 10.4 SYP GFAP
34 tetraploidy 10.3
35 glomangioma 10.3 VIM SYP
36 medullomyoblastoma 10.3 SYP GFAP
37 laryngeal neuroendocrine tumor 10.3 SYP SMARCB1
38 mixed glioma 10.3 NES GFAP
39 binswanger's disease 10.3 SYP GFAP
40 secretory meningioma 10.3 VIM SMARCB1
41 papillary adenoma 10.3 VIM SYP
42 large cell medulloblastoma 10.3 VIM SYP MET
43 angiocentric glioma 10.3 VIM SYP GFAP
44 myoepithelial carcinoma 10.3 VIM SMARCB1 GFAP
45 meningioma, radiation-induced 10.3 VIM SMARCB1 GFAP
46 chordoid meningioma 10.3 VIM SYP GFAP
47 dysembryoplastic neuroepithelial tumor 10.2 SYP NES GFAP
48 myoepithelioma 10.2 VIM SMARCB1 GFAP
49 gliomatosis cerebri 10.2 SYP NES GFAP
50 rare tumor 10.2

Graphical network of the top 20 diseases related to Ependymoblastoma:

Diseases related to Ependymoblastoma

Symptoms & Phenotypes for Ependymoblastoma

UMLS symptoms related to Ependymoblastoma:

vomiting, headache

MGI Mouse Phenotypes related to Ependymoblastoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.5 GFAP LIN28A MET MYCN NGF SMARCB1
2 nervous system MP:0003631 9.28 ENO2 GFAP LIN28A MET MYCN NGF

Drugs & Therapeutics for Ependymoblastoma

Drugs for Ependymoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 246)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Donepezil Approved Phase 3 120014-06-4 3152
Ondansetron Approved Phase 3 99614-02-5 4595
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
Etoposide Approved Phase 3 33419-42-0 36462
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
leucovorin Approved Phase 3 58-05-9 6006 143
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
Ifosfamide Approved Phase 3 3778-73-2 3690
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
18 Grape Approved Phase 3
19 Cranberry Approved, Investigational Phase 3
Daunorubicin Approved Phase 3 20830-81-3 30323
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
Histamine Approved, Investigational Phase 3 51-45-6 774
Cyproheptadine Approved Phase 3 129-03-3 2913
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
Camptothecin Experimental Phase 3 7689-03-4
28 Analgesics Phase 3
29 Liver Extracts Phase 3
30 Antiemetics Phase 3
31 Cholinesterase Inhibitors Phase 3
32 Cholinergic Agents Phase 3
33 Emetics Phase 3
34 Cola Phase 3
35 Anesthetics Phase 3
36 Narcotics Phase 3
37 Analgesics, Opioid Phase 3
38 Anesthetics, General Phase 3
39 Anesthetics, Intravenous Phase 3
40 Etoposide phosphate Phase 3
41 Vitamin B Complex Phase 3
42 Immunosuppressive Agents Phase 3
43 Folate Phase 3
44 Folic Acid Antagonists Phase 3
45 Tubulin Modulators Phase 3
46 Antirheumatic Agents Phase 3
47 Vitamin B9 Phase 3
48 Antimitotic Agents Phase 3
49 Micronutrients Phase 3
50 Vitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 187)
# Name Status NCT ID Phase Drugs
1 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
2 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
3 Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
4 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
5 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
6 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Active, not recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
8 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
9 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
10 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate Active, not recruiting NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
11 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
12 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
13 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
14 Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy Unknown status NCT00180791 Phase 2 Etoposide, carboplatin, melphalan, cisplatin, thiotepa
15 Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours Unknown status NCT00274911 Phase 2 cisplatin;lomustine;vincristine sulfate
16 A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy Unknown status NCT02624388 Phase 2 Genistein;Placebo
17 A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM Completed NCT01977677 Phase 1, Phase 2 temozolomide;plerixafor
18 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
19 Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2 Zalypsis
20 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
21 A Phase II Study of Pemetrexed in Children With Recurrent Malignancies Completed NCT00520936 Phase 2 pemetrexed
22 Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET Completed NCT01542736 Phase 2 Carboplatin;Vincristine
23 A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors Completed NCT00563680 Phase 2 AMG 479
24 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
25 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
26 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
27 A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors Completed NCT00030667 Phase 2 imatinib mesylate
28 A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas Completed NCT00070109 Phase 2 trabectedin
29 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
30 A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma Completed NCT00330421 Phase 2 sorafenib tosylate
31 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
32 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
33 A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET Completed NCT00668148 Phase 2
34 A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies Completed NCT02116777 Phase 1, Phase 2 Talazoparib;Temozolomide
35 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
36 Phase II Trial of Gleevec (STI571) in Therapy of Ewing's Family of Tumors and Desmoplastic Small Round Cell Tumors Completed NCT00062205 Phase 2 imatinib mesylate
37 Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years Completed NCT00936156 Phase 2 Chemotherapy (carboplatin, etoposide, thiotepa)
38 A Randomized Phase II Study of Bevacizumab (NSC 704865) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma Completed NCT00516295 Phase 2 topotecan hydrochloride;vincristine sulfate;cyclophosphamide
39 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
40 Phase II Study of Antineoplastons A10 and AS2-1 In Children With Primitive Neuroectodermal Tumors Completed NCT00003460 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
41 A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors Completed NCT00047177 Phase 2 Oxaliplatin
42 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
43 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
44 A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors. Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel;nab-paclitaxel
45 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
46 A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT) Completed NCT00055952 Phase 2 exatecan mesylate
47 A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias Completed NCT01154816 Phase 2 Alisertib
48 A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
49 Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
50 Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support Completed NCT00003211 Phase 2 amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate

Search NIH Clinical Center for Ependymoblastoma

Genetic Tests for Ependymoblastoma

Anatomical Context for Ependymoblastoma

MalaCards organs/tissues related to Ependymoblastoma:

Brain, T Cells, Lung, Bone, Spinal Cord, Liver, Bone Marrow

Publications for Ependymoblastoma

Articles related to Ependymoblastoma:

(show top 50) (show all 249)
# Title Authors PMID Year
Tumor suppressor proteins are differentially affected in human ependymoblastoma and medulloblastoma cells exposed to nerve growth factor. 61 54
17453820 2007
In vitro human ependymoblastoma cells differentiate after exposure to nerve growth factor. 54 61
15906158 2004
Expression of non-glial intermediate filament proteins in gliomas. 54 61
7518371 1994
Radiation for ETMR: Literature review and case series of patients treated with proton therapy. 61
30582019 2019
Embryonal tumor with multilayered rosettes, C19MC-altered (ETMR): a newly defined pediatric brain tumor. 61
31934159 2019
A Congenital Case of Ependymoblastoma: A Rare and Aggressive Brain Tumor. 61
29432310 2019
Embryonal Tumor with Multilayered Rosettes in a 3-Year-Old Girl: Case Report. 61
28191622 2019
Sellar Embryonal Tumor: A Case Report and Review of the Literature. 61
30459893 2018
Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. 61
29248974 2018
LIN28A, a sensitive immunohistochemical marker for Embryonal Tumor with Multilayered Rosettes (ETMR), is also positive in a subset of Atypical Teratoid/Rhabdoid Tumor (AT/RT). 61
28744687 2017
Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC). 61
28508928 2017
Lymph node metastasis of presacral ependymoblastoma in a young child. 61
28215462 2017
Embryonal Tumor With Abundant Neuropil and True Rosettes: A Distinct Immunohistochemical Pattern. 61
26658063 2016
Embryonal tumors with multilayered rosettes in children: the SFCE experience. 61
26438544 2016
Review of the Dielectric Properties of Animal and Human Tumors Determined from In Vivo Measurements. 61
29199579 2016
Pediatric brain tumors in a low/middle income country: does it differ from that in developed world? 61
26514358 2016
Sacrococcygeal ependymoblastoma. 61
26493054 2015
Embryonal tumor with multilayered rosettes of the fourth ventricle: case report. 61
26252622 2015
Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. 61
25916887 2015
Posterior fossa ependymoblastoma diagnosed in the second month of life: uneventful 12 years survival after gross total resection followed by chemotherapy. 61
26251773 2015
[Embryonal Tumors with Multilayer Rosettes--Rare Central Nervous System Tumors in Infants]. 61
26299744 2015
MET T992I mutation in a case of ependymoblastoma/embryonal tumour with multilayered rosettes. 61
25194039 2014
MRI characteristics of ependymoblastoma: results from 22 centrally reviewed cases. 61
24948504 2014
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. 61
24839957 2014
Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. 61
24337497 2014
MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system . 61
24470553 2014
[Primitive neuroectodermal tumor of central nervous system with features of ependymoblastoma and neuroblastoma: a clinicopathologic study of 4 cases]. 61
25208992 2014
Ependymoblastoma with cystic change in a child. 61
24724717 2014
Ependymoblastoma of the brainstem: MRI findings and differential diagnosis. 61
24464920 2014
A case report of an ependymoblastoma in the rectovaginal space and a review of the literature. 61
24511018 2014
Embryonal tumor with multilayered rosettes: diagnostic tools update and review of the literature. 61
23863344 2014
The role of CD133+ cells in a recurrent embryonal tumor with abundant neuropil and true rosettes (ETANTR). 61
23865520 2014
Review of temperature dependence of thermal properties, dielectric properties, and perfusion of biological tissues at hyperthermic and ablation temperatures. 61
25955712 2014
Anaplastic ependymoma with ependymoblastic multilayered rosettes. 61
23791209 2013
Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. 61
23223339 2013
[Are the medulloepithelioma, ependymoblastoma and embryonal tumor with multilayered rosettes the same entity?]. 61
24558755 2013
Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. 61
22324795 2012
Embryonal tumor with multilayered rosettes: Two case reports with a review of the literature. 61
22406791 2012
Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with a focal amplification at chromosome 19q13.42 locus: further evidence of two new instances in China. 61
21481009 2011
Ependymoblastoma in an adult: a diagnostic challenge on cytology. 61
22674109 2011
TP53, β-Catenin and c-myc/N-myc status in embryonal tumours with ependymoblastic rosettes. 61
21073496 2011
Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. 61
21308398 2011
Supratentorial PNET in a young child. 61
21213074 2011
Embryonal tumors with abundant neuropil and true rosettes: 2 illustrative cases and a review of the literature. 61
21194275 2011
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. 61
20712019 2010
Molecular diagnostics of CNS embryonal tumors. 61
20882288 2010
Embryonal tumor with abundant neuropil and true rosettes (ETANTR): a new distinctive variety of pediatric PNET: a case-based update. 61
20499240 2010
[Intramedullary tumors. Results of a national investigation in private neurosurgery]. 61
20097390 2010
Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. 61
20407781 2010
Ependymoblastoma: dear, damned, distracting diagnosis, farewell!*. 61
19120373 2010

Variations for Ependymoblastoma

Expression for Ependymoblastoma

Search GEO for disease gene expression data for Ependymoblastoma.

Pathways for Ependymoblastoma

Pathways related to Ependymoblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
3 11.38 VIM NES MET LIN28A

GO Terms for Ependymoblastoma

Cellular components related to Ependymoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament cytoskeleton GO:0045111 8.8 VIM NES GFAP

Biological processes related to Ependymoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 9.32 VIM GFAP
2 astrocyte development GO:0014002 9.26 VIM GFAP
3 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.16 MYCN LIN28A
4 Bergmann glial cell differentiation GO:0060020 8.96 VIM GFAP
5 intermediate filament-based process GO:0045103 8.62 VIM GFAP

Sources for Ependymoblastoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....